Keymed Biosciences Inc. (2162.HK)
HKD 33.0
(-1.93%)
HKD 33.0
(-1.93%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -269.76 Million CNY | -4.06% |
| 2022 | -259.25 Million CNY | 93.28% |
| 2021 | -3.86 Billion CNY | -391.34% |
| 2020 | -785.7 Million CNY | -424.16% |
| 2019 | -71.83 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -177.89 Million CNY | 11.91% |
| 2024 Q2 | -177.89 Million CNY | 0.0% |
| 2023 Q3 | -201.94 Million CNY | -21101.89% |
| 2023 FY | - CNY | -4.06% |
| 2023 Q4 | -201.94 Million CNY | 0.0% |
| 2023 Q1 | -952.5 Thousand CNY | 99.54% |
| 2023 Q2 | -952.5 Thousand CNY | 0.0% |
| 2022 Q2 | -54.43 Million CNY | 0.0% |
| 2022 FY | - CNY | 93.28% |
| 2022 Q1 | -54.43 Million CNY | 20.41% |
| 2022 Q4 | -206.67 Million CNY | 0.0% |
| 2022 Q3 | -206.67 Million CNY | -279.71% |
| 2021 FY | - CNY | -391.34% |
| 2021 Q4 | -68.39 Million CNY | 0.0% |
| 2021 Q3 | -68.39 Million CNY | 35.15% |
| 2021 Q2 | -105.45 Million CNY | 0.0% |
| 2021 Q1 | -105.45 Million CNY | -125.82% |
| 2020 Q4 | -46.69 Million CNY | 0.0% |
| 2020 FY | - CNY | -424.16% |
| 2020 Q2 | -20.84 Million CNY | 0.0% |
| 2020 Q3 | -46.69 Million CNY | -124.05% |
| 2020 Q1 | -20.84 Million CNY | 0.0% |
| 2019 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 395.688% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 155.417% |